| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD135; FLK-2; FLT-3; FLT3; STK-1 |
| Entrez GeneID | 2322; |
| WB Predicted band size | 130 160 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around aa.589~593 (Y-F-Y-V-D) derived from Human FLT3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FLT3(Ab-591)抗体的模拟参考文献示例，基于典型研究场景构建，供参考：
---
1. **文献名称**: *"FLT3 Surface Expression in Acute Myeloid Leukemia: Prognostic Impact and Detection by Monoclonal Antibody Ab-591"*
**作者**: Smith A, et al.
**摘要**: 本研究使用FLT3(Ab-591)抗体通过流式细胞术分析AML患者样本，发现FLT3的高表达与化疗耐药性和总生存率降低显著相关。抗体特异性经敲除细胞系验证。
2. **文献名称**: *"Validation of FLT3(Ab-591) for Immunoblotting in Mutant FLT3-ITD Studies"*
**作者**: Johnson R, et al.
**摘要**: 文章验证了FLT3(Ab-591)在Western blot中检测FLT3-ITD突变蛋白的性能，证实其在区分突变型与野生型FLT3中的高灵敏度，适用于基础研究中的蛋白表达分析。
3. **文献名称**: *"FLT3 Antibody-Based Isolation of Leukemic Stem Cells in Murine Models"*
**作者**: Lee H, et al.
**摘要**: 利用FLT3(Ab-591)进行免疫磁珠分选，成功从小鼠白血病模型中分离出FLT3阳性白血病干细胞，并揭示其自我更新依赖FLT3信号通路的机制。
4. **文献名称**: *"Comparative Evaluation of Commercial FLT3 Antibodies in Diagnostic Immunohistochemistry"*
**作者**: Brown K, et al.
**摘要**: 研究对比了包括Ab-591在内的多种FLT3抗体在AML骨髓活检中的表现，发现Ab-591在石蜡切片中染色一致性最佳，推荐用于临床病理诊断。
---
**备注**：以上文献为示例性质，实际引用需通过学术数据库(如PubMed、Google Scholar)以“FLT3 Ab-591”或抗体货号(如Abcam产品可查其官网参考文献)检索真实研究。部分厂商会提供抗体在已发表研究中的使用案例。
The FLT3 (Ab-591) antibody targets FMS-like tyrosine kinase 3 (FLT3), a type III receptor tyrosine kinase critical for hematopoietic stem cell proliferation, differentiation, and survival. FLT3 is primarily expressed in early hematopoietic progenitor cells and plays a key role in normal blood cell development. However, mutations in FLT3. such as internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutations, are frequently observed in acute myeloid leukemia (AML), leading to constitutive activation of downstream signaling pathways (e.g., PI3K/AKT, MAPK/ERK) and uncontrolled cell growth. These mutations are associated with poor prognosis, making FLT3 a significant therapeutic target in AML research.
The FLT3(Ab-591) antibody is designed to detect and study FLT3 expression, activation, and mutational status in experimental models. It is commonly used in techniques like Western blotting, immunohistochemistry, or flow cytometry to assess FLT3 protein levels or phosphorylation states in leukemic cells. Additionally, this antibody may aid in evaluating the efficacy of FLT3 inhibitors, which are emerging as targeted therapies for FLT3-mutant AML. Its specificity for FLT3 allows researchers to explore mechanisms of drug resistance, monitor disease progression, or identify patient subsets likely to benefit from FLT3-targeted treatments. As a research tool, FLT3(Ab-591) contributes to both basic understanding of FLT3 biology and translational studies aimed at improving clinical outcomes in hematologic malignancies.
×
